Paper · 28296676
Histopathologic Features of Colitis Due to Immunotherapy With Anti-PD-1 Antibodies.
Chen JH and 3 others. Am J Surg Pathol, 2017. Cited by 151 papers, by iCite.
11 sourcespapers-2026-11-12-0.1.0
Cite this record
ConductScience Library. Histopathologic Features of Colitis Due to Immunotherapy With Anti-PD-1 Antibodies. Papers, record 28296676. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/28296676
On this page
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics27
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Antibodies | Major topic |
| Antineoplastic Agents | Major topic |
| Colitis | Major topic |
| Colon | Major topic |
| Immunotherapy | Major topic |
| Programmed Cell Death 1 Receptor | Major topic |
| Adult | |
| Aged | |
| Aged, 80 and over | |
| Anti-Inflammatory Agents | |
| Apoptosis | |
| Atrophy | |
| Biopsy | |
| Colectomy | |
| Colitis, Lymphocytic | |
| Colonoscopy | |
| Diagnosis, Differential | |
| Enterocolitis, Pseudomembranous | |
| Female | |
| Humans | |
| Inflammatory Bowel Diseases | |
| Male | |
| Middle Aged | |
| Predictive Value of Tests | |
| Remission Induction | |
| Retrospective Studies | |
| Severity of Illness Index |
Source PubMed
Grants0
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
None in this release.
Trials0
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
None in this release.
Comments and corrections0
PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.
None in this release.
References0
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
None in this release.
Cited by84
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 151 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42,979,397 | Immunobiology and Immune-Related Toxicities of Cancer Immunotherapy: Organ-Specific Immune-Related Adverse Events, Cytokine Release Syndrome, and Immune Effector Cell-Associated Neurotoxicity Syndrome. | J Brown Hosp Med | 2026 | https://conductscience.org/library/papers/42979397 | PubMed |
| 42,871,980 | Immune checkpoint inhibitors and the inflammatory dysregulation: decoding cutaneous and gastrointestinal immune-related adverse events for the allergist and immunologist. | Front Immunol | 2026 | https://conductscience.org/library/papers/42871980 | PubMed |
| 41,992,000 | Microbiota and immune-related adverse events in cancer immunotherapy. | Nat Rev Cancer | 2026 | https://conductscience.org/library/papers/41992000 | PubMed |
| 41,705,138 | Gastrointestinal adverse events following brentuximab vedotin and polatuzumab vedotin therapy. | Ther Adv Med Oncol | 2026 | https://conductscience.org/library/papers/41705138 | PubMed |
| 41,481,270 | When Checkpoint Inhibitors Break Barriers: Mechanisms and Challenges of irAEs of the Skin, Gastrointestinal Tract, and Lung. | Clin Cancer Res | 2026 | https://conductscience.org/library/papers/41481270 | PubMed |
| 41,284,018 | Rare non-neoplastic gastrointestinal diseases-drugs and bugs. | Pathologie (Heidelb) | 2026 | https://conductscience.org/library/papers/41284018 | PubMed |
| 40,872,602 | From Innovation to Complication: A Case Report and Review on Immune-Related Colitis Induced by ICIs. | Pharmaceuticals (Basel) | 2025 | https://conductscience.org/library/papers/40872602 | PubMed |
| 40,769,948 | Collagenous colitis in patients treated for cancer: role of immune checkpoint inhibitors. Clinical, histological and immunological features in 15 cases. | Histopathology | 2025 | https://conductscience.org/library/papers/40769948 | PubMed |
| 40,677,571 | Endoscopic insights into digestive-related adverse effects of immune checkpoint inhibitors: A narrative review. | World J Gastrointest Endosc | 2025 | https://conductscience.org/library/papers/40677571 | PubMed |
| 40,406,101 | Bibliometric analysis of traditional Chinese medicine in cancer treatment via immune system modulation (2015-2025). | Front Immunol | 2025 | https://conductscience.org/library/papers/40406101 | PubMed |
1 to 10 of 84
See all 84 cited byGenes2
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| CTLA4 | 1,493 | PubTator's text mining | https://conductscience.org/library/genes/1493 | NCBI Gene |
| PDCD1 | 5,133 | PubTator's text mining | https://conductscience.org/library/genes/5133 | NCBI Gene |
Drugs0
The drugs whose trials, in the Pipelines release, list the paper.
None in this release.
Data0
The data bank entries PubMed's record names. Trial numbers are under Trials.
None in this release.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/28296676
GET https://conductscience.org/api/papers/v1/28296676/cited_by?page=2